In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Market Domination hosts Julie Hyman and Josh Lipton report on the analyst note, also noting Novo Nordisk's (NVO) and Roche's (ROG.SW, RHHBY) own plans for experimental obesity pills. In an August ...